Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Fox, Edward J ^a   Salk, Jesse J ^a,b   Loeb, Lawrence A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CANCER GROWTH; DNA REPAIR; DNA SEQUENCE; GENE MUTATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR EVOLUTION; MUTATION RATE; MUTATIONAL ANALYSIS; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL TRANSFORMATION; GENETICS; HUMAN GENOME; MUTATION; NEOPLASM;

AGING; CELL TRANSFORMATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MUTATION; MUTATION RATE; NEOPLASMS;

EID: 84961720110     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0286-z     Document Type: Note

References (10)

1. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979-93.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
3. Alexandrov LBB, Nik-Zainal S, Wedge DCC, Campbell PJJ, Stratton MRR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3:246-59.
4. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47:1402-7.
5. Shen JC, Rideout WM, Jones PA. High frequency mutagenesis by a DNA methyltransferase. Cell. 1992;71:1073-80.
6. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 1974;34:2311-21.
7. Tomasetti C, Vogelstein B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347:78-81.
8. Fox EJ, Loeb LA. Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin Cancer Biol. 2010;20:353-9.
9. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:141119140020009.
10. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012;109:14508-13.